Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Short Interest Down 25.3% in August

Key Points

• Short interest in Shionogi & Co., Ltd. Unsponsored ADR decreased by 25.3% in August, dropping to 52,200 shares from 69,900 in July.
• The company reported $0.16 earnings per share for its last quarter, exceeding analysts' expectations of $0.14, despite revenues of $672.90 million falling short of estimates.
• Shionogi's stock performance reflects a 1-year low of $6.53 and a high of $9.14, with the current stock price at $8.99.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY - Get Free Report) saw a large decrease in short interest in the month of August. As of August 15th, there was short interest totaling 52,200 shares, adecreaseof25.3% from the July 31st total of 69,900 shares. Based on an average trading volume of 199,500 shares, the short-interest ratio is currently 0.3 days. Based on an average trading volume of 199,500 shares, the short-interest ratio is currently 0.3 days.

Shionogi & Co., Ltd. Unsponsored ADR Stock Performance

Shares of Shionogi & Co., Ltd. Unsponsored ADR stock opened at $8.99 on Monday. The company has a 50 day moving average of $8.65 and a 200-day moving average of $8.24. Shionogi & Co., Ltd. Unsponsored ADR has a 1-year low of $6.53 and a 1-year high of $9.14. The company has a quick ratio of 6.13, a current ratio of 6.63 and a debt-to-equity ratio of 0.01.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY - Get Free Report) last released its quarterly earnings data on Monday, July 28th. The company reported $0.16 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.14 by $0.02. The company had revenue of $672.90 million for the quarter, compared to analyst estimates of $719.55 million. Research analysts expect that Shionogi & Co., Ltd. Unsponsored ADR will post 0.66 earnings per share for the current fiscal year.

About Shionogi & Co., Ltd. Unsponsored ADR

Shionogi & Co, Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.